Endpoints News

Glaswegian chemistry startup Chemify has raised over $50M in a Series B to scale what it calls a "chemputer" system. https://lnkd.in/gCW4CbYT

Tomorrow: ESMO 2025 delivered pivotal cancer trial data. Join Endpoints for strategic analysis of what matters most. Register to watch: https://lnkd.in/djeJaBX2

NEW: Glasgow, Scotland-headquartered Chemify Limited has raised a Series B of just over $50 million, planning to use the funds to scale up its molecule-making approach to the US and beyond. I talked with CEO Lee Cronin about its focus on synthesizability of molecules by using their "chemputer" platform built on his programming language for chemistry. That focus differs from much of the AI bio world using models to discover new drug candidates — but maybe not the steps needed to make in the real world. “The number one problem with all of AI drug discovery is they do not produce the code to make their molecule,” Cronin said in an interview. “Chemify is coming to the rescue for everybody.” My latest for Endpoints News: https://lnkd.in/eQ2QRpby

CRISPR Therapeutics' called its latest gene editing tool “a significant advance" over prime editing. But Prime Medicine, Inc. disagrees. https://lnkd.in/eEWUVJ7b

🚨 Breaking: Novo Nordisk's chair steps down. https://lnkd.in/eCk_nxrt

Galapagos is shutting down its cell therapy arm as it couldn't find a buyer or other ways to divest the business. The company estimates it will lay off 365 workers. https://lnkd.in/eUKtCbyk

The "decade of ADCs" continues, and they're expected to become the backbone of cancer care, as AstraZeneca, Kelun-Biotech and Merck Group take the stage at #ESMO25 https://lnkd.in/eHCPyEyi

RAPT, Jeyou are gearing up for a Phase 3 trial after promising mid-stage results in urticaria. https://lnkd.in/e8GZATqZ

Novartis is looking to expand Pluvicto to earlier prostate cancer but questions remain. https://lnkd.in/eYWEUtVv

Alphamedix – a radiopharmaceutical developed by Sanofi and Orano – shines at #ESMO25 after it announced positive mid-stage trial results for a rare cancer. https://lnkd.in/eWAz5GXR